NurExone Biologic Inc.

Recent News

NurExone Announces Appointment of New Director and Provides Corporate Updates
Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - July 7, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) ("NurExone" or the "Company") is pleased to announce that, effective July 6, 2023, Dr. Gadi Riesenfeld has been appointed to the board of directors of the Company replacing Mr. Ron Mayron, who resigned for personal reasons.Dr. Riesenfeld has served on the board of directors and as president of several bio-pharmaceutical companies, including Kamapharm Ltd., Galisar Ltd., and OticPharma. Moreover, he...
2023-07-07 9:23 AM EDT
NurExone Engages Investor Relations Service Provider
Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - May 12, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, announced that it has engaged Litchfield Hills Research, LLC ("Litchfield") to perform investor relations services and activities, as defined in accordance with the policies of the TSX Venture Exchange ("TSXV") and applicable securities laws.Pursuant to the agreement with Litchfield, the Company...
2023-05-12 8:00 AM EDT
NurExone Announces Equity Incentive Plan Grants and Director Resignation
Toronto, Ontario and Tel Aviv, Israel--(Newsfile Corp. - May 8, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, announces that it has granted an aggregate of 1,145,520 incentive stock options ("Options") and 1,275,000 restricted share units ("RSUs") under the Company's equity incentive plan to certain officers and directors of the Company. Each Option is exercisable for one common share of...
2023-05-08 8:51 AM EDT
United States Patent Office Allows Patent to Exosome Biomedical Company NurExone
Haifa, Israel and Calgary, Alberta--(Newsfile Corp. - January 12, 2023) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, has received a notice of allowance from the United States Patent and Trademark Office ("USPTO") for U.S. Patent Application NO. 17/042,441 ("the Patent"). The Patent covers and protects NurExone Exo-PTEN technology, and its drug composition as well as methods for non-invasive intranasal administration of...
2023-01-12 8:51 AM EST
NurExone Issues Annual Shareholder Letter
Calgary, Alberta--(Newsfile Corp. - December 15, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) ("we", "our", the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, is pleased to provide the following shareholder letter from NurExone CEO Dr. Lior Shaltiel.Dear Shareholders, We started our journey to provide much-needed therapy for people who have suffered spinal cord injuries and have accomplished very significant achievements in 2022. As we progress with developing...
2022-12-15 8:30 AM EST
NurExone Announces Completion of Securites for Debt Settlement
Calgary, Alberta--(Newsfile Corp. - December 7, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it completed its securities for debt settlement on December 6, 2022, previously announced by the Company on November 24, 2022. The Company agreed to settle debts in the aggregate amount of CAD$46,523.69 with the issuance of 122,430 common shares...
2022-12-07 6:17 PM EST
Update: NurExone Biologic Successfully Demonstrates its Patent-Pending Platform Technology for Loading Exosomes with Therapeutic Molecules
NurExone is providing an updated release to the previously disseminated release from yesterday to replace several sentences and figures that were included in error.Calgary, Alberta--(Newsfile Corp. - December 1, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, reported today results of a pre-clinical loading efficiency study that was completed by the Company showing that its innovative and proprietary loading technology...
2022-12-01 2:30 PM EST
NurExone Biologic Successfully Demonstrates its Patent-Pending Platform Technology for Loading Exosomes with Therapeutic Molecules
Calgary, Alberta--(Newsfile Corp. - November 30, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, reported today results of a pre-clinical loading efficiency study that was completed by the Company showing that its innovative and proprietary loading technology has the potential to serve as an efficient process for loading of therapeutic molecular cargo into exosomes. In exosome-based therapies, loaded exosomes are...
2022-11-30 8:30 AM EST
NurExone Announces Securities for Debt Settlement
Calgary, Alberta--(Newsfile Corp. - November 24, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it has agreed to settle debts in the amount of CAD$46,523.69 with the issuance of 122,430 common shares of the Company at a deemed price of CAD$0.38 per share.These debts were incurred prior to the recent Reverse Takeover Transaction following which...
2022-11-24 7:17 PM EST
NurExone Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Calgary, Alberta--(Newsfile Corp. - November 24, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, released a corporate update and reported financial results for the quarter ended September 30, 2022."Obtaining U.S. FDA approval for our drug platform remains a priority for NurExone and we intend to continue working towards expediting this process by submitting a Pre-IND meeting request," said Dr. Lior...
2022-11-24 8:00 AM EST

Have you heard? TMX Group has acquired Newsfile

NurExone Biologic Inc.

Recent News

Get News by Email

Stock Quote

RSS Feeds

Regulatory Filings

Tell Us Your Story

Cookie Settings

Have you heard? TMX Group has acquired Newsfile

Get News by Email

Stock Quote

RSS Feeds

Regulatory Filings

Tell Us Your Story